Market Overview

UPDATE: Piper Jaffray Reiterates Overweight Rating, Raises PT on Isis Pharmaceuticals

Share:
Related ISIS
Benzinga's Top #PreMarket Losers
Morning Market Losers
Notable earnings before Friday's open (Seeking Alpha)

In a report published Wednesday, Piper Jaffray & Co. reiterated its Overweight rating on Isis Pharmaceuticals (NASDAQ: ISIS), and raised its price target from $15.00 to $18.00.

Piper Jaffray noted, “ISIS is the leading antisense company with a rich pipeline of drugs in development. The primary driver for ISIS shares remains KYNAMRO with European approval this year and a January 29, 2013 PDUFA date. While ISIS shares have risen considerably since May 1st, we look for continued upside driven by KYNAMRO approval, clinical data read-outs and new partnerships. ISIS remains a Top Pick for 2H:12.”

Isis Pharmaceuticals closed Tuesday at $13.74.

Latest Ratings for ISIS

DateFirmActionFromTo
Feb 2015Piper JaffrayDowngradesOutperformNeutral
Jan 2015Deutsche BankMaintainsBuy
Dec 2014JP MorganMaintainsNeutral

View More Analyst Ratings for ISIS
View the Latest Analyst Ratings

Posted-In: Piper Jaffray & Co.Analyst Color Price Target Analyst Ratings

 

Related Articles (ISIS)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→